Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Amgen’s evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia... Learn More
Recorded live on October 22, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
This exciting one-day seminar provides attendees with a unique opportunity to hear in-depth analysis of hot topics and trends concerning global biosimilars while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
November 20, 2014
Allergan’s Semprana and CoLucid’s Lasmiditan, Two Novel Acute Migraine Therapies, Will Drive Market Growth Through 2023
November 18, 2014
Zytiga is Currently the Most Commonly Prescribed Second-Line Therapy for Metastatic Castrate-Resistant Prostate Cancer, According to Surveyed European Oncologists
November 12, 2014
The Ulcerative Colitis Market Will Grow Over the Next Decade, Reaching $4.2 Billion in 2023
Launch of Novel Oral HIF-PH Inhibitors Will Intensify the Competition for Renal Anemia Patient Share
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake... Read More
Argentina: Pricing and Reimbursement Process
Insight Accelerators are part of our Market Access Tracker service. In addition to the in-depth coverage provided in... Read More
Argentina: Market Access Tracker - 2014
Last Updated 20 November 2014Argentina, the fourth-largest pharmaceutical market in Latin America,... Read More